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Abstract
Background: A lack of sensitive and specific biomarkers is a major reason for the high rate of
Primary hepatocellular carcinoma (HCC)-related mortality. The aim of this study was to investigate
potential proteomic biomarkers specific for HCC.
Methods: 81 patients with hepatitis B-related HCC and 33 healthy controls were randomly
divided into a training set (33 HCC, 33 controls) and a testing set (48 HCC, 33 controls). Serum
proteomic profiles were measured using Surface-enhanced laser desorption/ionization-time-of-
flight mass spectroscopy (SELDI-TOF-MS).) A classification tree was established by Biomarker
Pattern Software (BPS). Candidate SELDI peaks were isolated by tricine-SDS-PAGE, identified by
HPLC-MS/MS and validated by immunohistochemistry (IHC) in liver tissues.
Results: A total of 6 proteomic peaks (3157.33 m/z, 4177.02 m/z, 4284.79 m/z, 4300.80 m/z,
7789.87 m/z, and 7984.14 m/z) were chosen by BPS to establish a classification tree with the highest
discriminatory power in the training set. The sensitivity and specificity of this classification tree
were 95.92%, and 100% respectively in the testing set. A candidate marker of about 7984 m/z was
isolated and identified as neutrophil-activating peptide 2 (NAP-2). IHC staining showed that NAP-
2 signals were positive in HCC tissues but negative in adjacent tissues.
Conclusion: The NAP-2 may be a specific proteomic biomarker of hepatitis B-related HCC.
1. Background
Primary hepatocellular carcinoma (HCC) is one of the
most lethal malignancies worldwide. It is the third leading
cause of cancer death in China and the sixth most com-
mon cancer in the world [1,2]. Prognosis of HCC remains
poor, mainly due to the failure of early diagnosis of the
disease in symptom-free patients [3,4]. In contrast, early
detection of HCC before the onset of clinical symptoms
can lead to curative treatment, significantly improving
prognosis [5,6].
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At present, alpha-fetoprotein (AFP) and des-γ-carboxy
prothrombin (DCP) are the two most widely used tests to
aid in the diagnosis and monitoring for HCC. However,
AFP is found to be normal in around one third of patients
with small (<3 cm) HCC [7], and the specificity of AFP is
only about 68.2% in detecting the patients with HCC [8].
Although DCP was believed to be a better marker for diag-
nosis of HCC, elevated DCP activity is only present in 44–
47% of HCCs less than 3 cm in size [9,10]. Thus, both AFT
and DCP are not ideal biomarkers for early diagnosis of
HCC. There is a pressing need to find new biomarkers for
more effective detection of HCC.
Recent advances in proteomic analysis have offered excit-
ing opportunities for finding novel biomarkers in biolog-
ical fluids. Today, two major strategies are used to discover
clinically useful biomarkers from a proteomic approach.
One of them utilizes a SELDI-TOF system [11-14], and the
other is a method based on 2-D PAGE coupled with MS
[15,16]. The SELDI-TOF, which generates the protein pat-
terns by MS, has been considered a powerful tool for the
discovery of new biomarkers [16,17]. However, almost all
of the proteins' peaks detected by SELDI are not easily
identified as protein molecules. Thus, these findings can-
not provide any information about the biological roles of
the marked proteins in the pathogenesis of a disease. On
the other hand, the 2-D PAGE-based method provides a
lot of information about proteins, including expression
volumes, actual p/s and molecular weights [18]. However,
the 2-D method is not sensitive for resolving hydropho-
bic, low abundant, low molecular weight proteins. LC-
MS/MS is a powerful identification tool for proteins, but
it is not suitable for analyzing proteins directly [18]. It has
been suggested that the combination of SELDI-TOF, 2-D
and LC-MS/MS may provide a better solution to identify
disease-associated proteomic biomarkers [18,16,19].
The aim of this study was to identify serum protein
biomarkers in HCC. The analysis was performed using
SELDI-TOF-MS technology to screen potential protein
patterns specific for HCC. Candidate protein peaks were
then separated by Tricine-SDS- PAGE and trypsin diges-
tion, identified by HPLC-MS/MS analysis and database
search, and confirmed by immunohistochemistry (IHC)
in liver tissues.
2. Results
2.1 Quality control of SELDI analysis
The reproducibility of SELDI spectra, i.e., mass location
and intensity from array to array on a single chip (intra-
assay) and between chips (inter-assay), was determined
using the pooled normal serum quality control samples.
Seven protein peaks in the range of 3,000–10,000 m/z on
the observed spectra were randomly selected to calculate
the coefficient of variance. The intra-assay and inter-assay
coefficient of variance for peak location was 0.05%, and
the intra-assay and inter-assay coefficients of variance for
normalized intensity (peak height or relative concentra-
tion) were 6% and 14% respectively (data not shown).
Masses that were within 0.08% mass accuracy between
spectra were considered to be the same. Most importantly,
it was observed that randomly selected samples, blinded
to the person performing SELDI and rerun months or
even a year later, were correctly classified by the decision
tree classification algorithm.
2.2 Protein peak detection and data preprocessing
Initially, we analyzed serum samples from the training set,
using the Ciphergen Biomarker pattern software. Among
126 qualified mass peaks (signal-to-noise ratio>5; ranging
from 2 to 50 km/z), 21 protein peaks were over-expressed,
whereas 44 protein peaks were significantly downregu-
lated in sera from HCC patients compared with those
from controls (all p values<0.05; Table 1). Fig. 1 shows an
example of the 7984 m/z peak that was up-regulated in
HCC samples vs. control samples.
To identify biomarkers with the potential to detect HCC,
the intensities of protein peaks in training set were trans-
ferred to BPS. A total of 6 peaks with the highest discrim-
inatory power (3157.33 m/z, 4177.02 m/z, 4284.79 m/z,
4300.80 m/z, 7789.87 m/z, and 7984.14 m/z) were auto-
matically selected to construct a classification tree (Table
2, 3). Fig. 2 shows the tree structure and sample distribu-
tion. This classification model distinguished serum sam-
ples based on their profiles of the protein peak intensities.
The classification tree using the combination of these 6
protein peaks identified 33 cases of HCC and 33 controls,
resulting in a sensitivity of 100% and a specificity of
96.97% respectively. (Table 4)
2.3 Validation of the serum proteomic profiles in testing set
To evaluate the accuracy and validity of the classification
tree generated from the training set, we determined the
performance of the classification model in our testing
dataset, consisting of 48 HCC and 33 of control samples.
Consistent with the results in training set, this classifica-
tion tree separated HCC samples from control samples
with a sensitivity of 100%, a specificity of 96.97%, and a
positive predictive value of 95.92%, respectively (Table
4). The area under the receiver operating characteristics
(ROC) curve of this model was 0.986, indicating possible
diagnostic utility.
2.4 Biomarker purification and identification
To isolate the proteins of interest and to determine candi-
date protein identities, 6 serum samples from HCC
patients containing high SELDI intensity of 7789 M/z and
7984 M/z were selected as potential candidate proteins for
isolation by Tricine-SDS-PAGE. Fig. 3 shows a picture ofProteome Science 2008, 6:10 http://www.proteomesci.com/content/6/1/10
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Comparisons of differential expressions of the SELDI peaks at 7984 m/z in HCC (1, 2) and healthy controls (3, 4) Figure 1
Comparisons of differential expressions of the SELDI peaks at 7984 m/z in HCC (1, 2) and healthy controls (3, 
4).
1
2
3
4
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the Tricine-SDS-PAGE gel separating two fractions of pro-
teins with approximate mass between 2.5 km/z and 11 k
m/z. The band with 8 m/z mobility that stained more
intensively in the gel was excised and trypsinised (Fig. 3).
After trypsin digestion of the 8 k m/z gel band, digested
peptides were measured by LC-MS/MS. 79 peptides,
including 45 unique peptides, were identified. Fig. 4 and
Fig. 5 show the peptide mass fingerprinting of the 7984
m/z band after trypsin digestion. Peptide mass lists
derived from spectra with high S/N ratio were submitted
to SWISS-PROT/TrAEMBL for database matching. By data-
base search, we found that the sequence of the 7984.14
m/z protein (pI>4) matched with the neutrophil-activat-
ing peptide MW = 8 019.36 m/z, pI = 8.43), a protein
known for its high expression in liver tumor tissues.
Diagram of the classification tree for patients with HCC and healthy controls Figure 2
Diagram of the classification tree for patients with HCC and healthy controls. The squares are the primary nodes 
and the circles indicate terminal nodes. The mass value in the root nodes is followed by the intensity value. For example, the 
question forming the first splitting rule is: Are the intensity levels of the peak at 4177.02 m/z lower or equal to 5.256? Samples 
that follow the rule go to the left "yes" terminal node, and samples that do not follow the rule go to a "no" daughter node to 
the right. The number of control or HCC samples in each node are shown.Proteome Science 2008, 6:10 http://www.proteomesci.com/content/6/1/10
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Table 1: Intensities of protein peaks between patients with HCC and controls
M/Z p value HCC patients Controls Expression of biomarkers
Mean SD Mean SD
4177.021 0 2.4109626 1.7831004 17.790127 12.3304 ↓
4284.793 1E-10 4.1675763 2.8210263 18.165137 10.96188 ↓
3157.338 2E-10 2.8711763 2.3671242 16.269795 12.3949 ↓
2210.294 4E-10 1.2477808 1.4009605 4.5723959 1.643278 ↓
3976.459 8E-10 2.6239766 3.4075661 10.778571 7.532834 ↓
2931.897 7.6E-09 3.1186882 2.0358896 11.507879 7.729 ↓
3954.075 1.11E-08 1.6472851 1.2559403 7.6936686 5.96494 ↓
7789.876 3.13E-08 21.662616 9.007951 8.8290885 6.779427 ↑
3190.271 3.9E-08 3.5195939 3.2358447 12.027547 8.698558 ↓
2880.784 7.45E-08 1.102611 1.3353521 5.001807 4.339702 ↓
2042.81 8.59E-08 5.2251662 4.7882565 15.394446 8.244651 ↓
4300.805 1.14E-07 6.3052246 2.8188831 14.24708 6.619937 ↓
2684.091 3.21E-07 3.262482 3.6567613 9.551285 5.764105 ↓
9312.108 3.21E-07 15.704431 4.4922866 8.8978734 4.287706 ↑
3272.949 8.18E-07 1.8316758 1.3430214 6.5194098 5.123064 ↓
8168.558 2.15E-06 4.2784744 1.7546221 2.2906521 1.328373 ↑
7984.144 1.12E-05 6.0715178 4.4504467 2.9324679 1.787027 ↑
2233.538 2.99E-05 1.9147055 1.5778554 4.0521515 2.028355 ↓
2188.991 3.54E-05 2.5010757 1.5294086 4.3043581 1.881263 ↓
2135.285 4.42E-05 3.6300916 3.49041 10.966854 9.955057 ↓
11713.42 4.67E-05 4.1459834 5.4995663 1.336294 3.257604 ↑
2053.145 5.5E-05 9.7060752 5.9603503 4.3023177 2.231138 ↑
11803.06 5.5E-05 1.6426482 1.3296893 0.7800243 0.476692 ↑
11913.52 6.47E-05 1.3968035 1.0639529 0.6868796 0.606584 ↑
7577.259 8.47E-05 6.5419175 6.7324834 2.9342635 2.346913 ↑
3328.797 9.93E-05 4.2466182 2.9569092 6.2898423 2.27614 ↓
2458.656 0.00011 5.1397003 9.6317988 12.275455 14.48544 ↓
2175.988 0.000116 2.7234278 1.2771298 4.1339189 2.387265 ↓
2760.934 0.000338 4.6648972 3.2035945 9.3423629 6.483809 ↓
2226.912 0.000452 2.355006 1.6168492 3.8420929 1.696412 ↓
3042.037 0.000575 2.0878758 1.5066385 3.9896521 2.661699 ↓
3315.627 0.000602 9.5689729 4.8592784 15.151073 7.432231 ↓
2025.722 0.000694 4.6839614 3.8381819 1.7500306 1.539545 ↑
2798.165 0.000694 2.0897574 2.4307372 3.9262301 3.225462 ↓
3142.417 0.000875 3.1393877 1.8539336 6.0137931 4.371349 ↓
3497.766 0.001004 1.9353972 2.3046427 4.1676774 3.520588 ↑
2604.949 0.001258 1.6948706 2.4206924 3.5161364 2.838326 ↓
2635.516 0.001316 1.8316855 2.6597455 3.412366 2.418701 ↓
1986.694 0.001503 3.9645947 2.1700129 6.1885737 2.961989 ↓
11546.56 0.001503 2.247573 3.0491879 0.6758139 1.142265 ↑
5811.636 0.00204 6.4141252 7.5516614 2.3012091 1.338683 ↑
10292.36 0.002223 1.8987997 1.2501286 1.0377238 0.735765 ↑
4118.351 0.003676 7.11073 5.1441046 11.680701 6.853008 ↓
3264.446 0.00668 6.9932534 5.2366332 11.0494 7.096711 ↓
2149.367 0.006943 3.7005272 3.7552454 5.9585474 5.335906 ↓
2011.105 0.007497 2.6144135 2.0116598 4.2731103 2.674531 ↓
2785.17 0.007497 2.5972155 2.4631704 4.4992097 3.047729 ↓
3472.829 0.00906 3.1882635 3.4294237 4.5476185 2.91472 ↓
5482.928 0.011735 4.8059806 2.9804352 3.4096367 2.533875 ↑
3923.203 0.01217 2.4220346 2.3048585 4.3790796 3.64184 ↓
2316.308 0.017976 3.4762243 3.7179706 1.6393136 1.780269 ↑
6845.999 0.01926 4.9948325 2.3817092 6.838496 3.161917 ↓
2692.421 0.019931 4.921541 2.7549713 3.457848 2.217777 ↑
3104.495 0.019931 1.3934316 1.4045028 2.3921117 1.843127 ↓
2753.121 0.021336 4.4069341 3.9525245 6.3553599 4.472233 ↓
3509.35 0.02207 4.5393277 3.3610221 7.2480107 5.319909 ↓Proteome Science 2008, 6:10 http://www.proteomesci.com/content/6/1/10
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2.5 Immunohistochemistry of NAP-2
NAP-2 expression in liver tumor tissues and adjacent liver
tissues was analyzed by immunohistochemistry using spe-
cific NAP-2 antibodies. Interestingly, strong brown stain-
ing signals were found in HCC tissues (Fig. 6A), while no
NAP-2 staining was found in adjacent liver tissues (Fig.
6B).
3. Discussion
In this study, we generated serum protein mass spectra
from hepatitis B-related HCC patients and controls. Based
on the serum proteomic profiles, we constructed a classi-
fier that accurately distinguishes HCC from controls. Val-
idation of this proteomic classifier in a separate
independent testing set showed high accuracy for discrim-
inating HCC cases from controls. One of the proteins
(7984 m/z) in the proteomic signature was identified as
neutrophil-activating peptide 2 (NAP-2), which was fur-
ther confirmed by IHC as a specific biomarker of hepatitis
B-related HCC.
A major strength of this study is the use of a two-step
workflow for proteomic biomarker screening. Several
reports have determined that class prediction results
should be corroborated in independent sample sets [20-
22]. To translate from proteomic peaks to proteomic sig-
natures for discriminating HCC patients from controls, we
used BPS to select the best proteomic peaks for construc-
tion of classification tree [23]. The classifier separated
patients with HCC from healthy controls with a sensitivity
of 100% and a specificity 93.94%. To confirm our find-
ings, we subsequently applied our trained classifier to a
second, independent test dataset, which was obtained by
a rigorous standardized protocol similar to that of train-
ing dataset but included a greater proportion of HCC
patients. In this new dataset, a classifier trained on the
spectra obtained in the first phase of the study discrimi-
nated HCC cases from controls with a sensitivity of 100%
and specificity of 96.97%. This percentage of correct clas-
sification was much higher than the currently accepted
biomarkers, such as AFP (46% sensitivity and 89% specif-
icity) [24]. Only one in 48 total HCC samples was mis-
classified. The fact that the diagnostic performance of the
training classifiers survived rigorous testing in testing
dataset strengthens the conclusions of the study in the
training dataset. Another strength of this study is the utili-
zation of comprehensive proteomic techniques including
protein profiling, Tricine-SDS-PAGE and HPLC-MS/MS
for detection, identification, and IHC for characterization
of NAP-2 as a biomarker in HCC.
Among the proteins identified by MS, one of the top three
up-regulated proteins was characterized to be the neu-
trophil-activating peptide 2 (NAP-2). NAP-2 is a major
form of CXCL7, a member of chemokine family involving
in regulating immunity, angiogenesis, stem cell traffick-
6203.673 0.02207 3.3648117 1.6676335 4.5994989 2.159071 ↓
9212.971 0.024405 43.945799 32.384871 24.707158 29.86224 ↑
4137.329 0.026951 5.4829547 2.9809693 7.0825919 2.943026 ↓
9421.615 0.032739 8.5502217 5.7753764 6.0635598 6.172742 ↑
5318.755 0.037162 5.2174103 6.0996661 10.364681 11.18352 ↓
2953.161 0.039559 9.7117587 7.368618 12.899569 8.162569 ↓
4599.027 0.040805 18.449161 16.04898 13.034537 17.97882 ↑
7988.252 0.042085 6.4870797 3.9637198 5.3343441 4.792026 ↑
4858.969 0.049004 4.0595446 4.2862607 5.63334 4.377429 ↓
↑:Protein peak intensity that was upregulated in the serum of HCC patient.
↓ : Protein peak intensity that was downregulated in the serum of HCC patient
Table 1: Intensities of protein peaks between patients with HCC and controls (Continued)
Table 2: The intensities of six protein peaks of the classification tree in patients and controls
M/Z p value HCC patients Controls Expression of biomarkers
Mean SD Mean SD
3157.338 2E-10 2.871176 2.367124 16.26979 12.3949 ↓
4177.021 0 2.410963 1.7831 17.79013 12.3304 ↓
4284.793 1E-10 4.167576 2.821026 18.16514 10.96188 ↓
4300.805 1.14E-07 6.305225 2.818883 14.24708 6.619937 ↓
7789.876 3.13E-08 21.66262 9.007951 8.829089 6.779427 ↑
7984.144 1.12E-05 6.071518 4.450447 2.932468 1.787027 ↑
11803.06 5.5E-05 1.642648 1.329689 0.780024 0.476692 ↑
↑:Protein peak intensity that was upregulated in the serum of HCC patient.
↓ : Protein peak intensity that was downregulated in the serum of HCC patientProteome Science 2008, 6:10 http://www.proteomesci.com/content/6/1/10
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ing, and mediating organ-specific metastases of cancers
[26]. Recent studies using SELDI-based serum proteome
profiling, in combination with immunoassays and West-
ern blot analysis, have identified CXCL7 as a marker of
advanced myelodysplastic syndromes (MDS), a hemato-
logic stem cell malignancies in elderly patients [13,25].
CXCL7 is translated as a propeptide, then cleaved to sev-
eral smaller forms each reported to have specific func-
tions. The shortest form, called NAP-2, is structurally
related to NAP-1/IL-8, which was shown to be highly
expressed in human hepatocellular carcinoma [26] and its
serum levels were correlated with clinicopathological fea-
tures and prognosis of HCC [27]. NAP-2 is a potent acti-
vator and attractant for human neutrophils in vitro and in
vivo [28]. The expression of NAP-2 mRNA was very low in
normal liver tissues but extremely high in liver tumor tis-
sues [29]. Interestingly, no expression of NAP-2 was
observed in tissues of other type of tumors, suggesting that
NAP-2 probably to be a specific biomarker of liver cancer.
Previous studies using either 2D-gel electrophresis or
SELDI-MS in HCC have provided evidence that proteomic
biomarkers can be used to discriminate HCC from
healthy controls. Reported protein biomarkers included
ferritin light chain [30], vitronectin [17], apolipoprotein
E, chloride intracellular channel 1 [14], liver aldolase, tro-
pomyosin β-chain, ketohexokinase, enoyl-CoA hydratase,
albumin, amooothelin, arginase-1 [31], complement C3a
[13], and brian derived neurotrophic factor (BDNF) [32].
Differences between previous studies and this present
study might result from the applied methods (compre-
hensive strategy vs  single approach), available samples
(e.g. serum vs tissue), sample preparation (e.g. fractiona-
tion), different protein chip (CM10, IMAC-Zn, IMAC-Cu,
WCX2), patient or control characteristics, and data analy-
sis with different algorithms.
4. Conclusion
In summary, we have identified a set of protein peaks that
could discriminate HCC from healthy controls. From the
protein peaks specific to HCC disease, we identified and
characterized neutrophil-activating peptide-2 as a poten-
tial proteomic biomarker of HCC. Further studies with
larger sample sizes will be needed to verify this specific
protein marker and to address its efficacy, especially with
regard to discriminating histologic types of HCC and dis-
ease stages. Nevertheless, our study demonstrates a
rational approach for identifying HCC biomarkers that
could be used for detection and monitoring HCC by pro-
teomic techniques.
5. Materials and methods
5.1 Patients and samples
With informed consent obtained from each participant,
serum samples were collected by the Department of Sur-
gery at the First Affiliated Hospital of Guangxi Medical
University, China. Patients with HCC were diagnosed
according to standard criteria put forth by the Chinese
Society of Liver Cancer [33]. The cancer group consisted of
48 patients with HCC. All HCC cases were histologically
confirmed, positive for hepatitis B antigen, and negative
for anti-hepatitis C. The controls were 33 healthy volun-
teers without liver neoplasia, alcoholic cirrhosis, hepatitis
B or hepatitis C infection, recruited from routine health
examination at the same hospital. The mean age was 46.0
years (ranges from 26 to 75 years) for HCC patients and
41.8 years (ranges from 23 to 60 years) for healthy con-
trols. The characteristics of all subjects are shown in Table
5. Sera of HCC patients was collected before any treat-
ment and randomly divided into two groups: training
group and testing group. All blood samples were colleted
in the morning before breakfast. Two milliliters of whole
blood were obtained and stored at 4°C for one hour and
then centrifuged for 10 minutes at 3000 r/min. All serum
samples were stored at -80°C before SELDI ProteinChip
analysis.
5.2 SELDI-TOF-MS analysis of serum protein profiles
Protein profiling of serum samples was performed using
the eight-spot format WCX2 (weak cationic exchange)
ProteinChip Arrays (Ciphergen Biosystems, Fremont, CA,
USA). Frozen serum samples were thawed and spun at
10,000 rpm for 5 min at 4°C. Twenty µl of U9 buffer was
added to 10 µl aliquots of each serum sample and placed
on ice for 30 min before adding 360 µl WCX-2 buffer.
Arrays were prepared as follows: each array was pre-equil-
ibrated 2 × 5 min in 200 µl WCX-2 buffer on a horizontal
shaker (MSI Minishaker) before sample addition. The
sample supernatant was added and incubated for 1 hr on
the shaker. After incubation, the sample was removed,
and each spot was washed with 200 µl WCX-2 buffer for 2
× 5 min with agitation. After washing, the array was care-
Table 3: Important peaks selected by BPS
M/z of candidate peaks Score
M4177_02 100.00 ||||||||||||||||||||||||||||||||||||||||||
M4284_79 89.84 ||||||||||||||||||||||||||||||||||||||
M3157_33 76.56 ||||||||||||||||||||||||||||||||
M7789_87 75.62 ||||||||||||||||||||||||||||||||
M4300_80 42.93 |||||||||||||||||
M7984_14 38.65 ||||||||||||||||
Table 4: Performance of the classification tree in the training and 
testing sets
Sets Groups Sensitivity Specificity
Training set 33cases/33 controls 100% (33/33) 93.94% (31/33)
Testing set 48cases/33 controls 100% (48/48) 96.97% (32/33)Proteome Science 2008, 6:10 http://www.proteomesci.com/content/6/1/10
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fully separated from the bioprocessor and washed briefly
with deionized water. 0.5 µl sinapinic acid (SPA) was
deposited on the array spots and allowed to air dry.
The ProteinChip Arrays were read by surface-enhanced
laser desorption/ionization time-of flight (SELDI-TOF-
MS) mass spectrometry (ProteinChip PBS II reader,
Ciphergen). This was calibrated using NP20 chips that
had been bound with all-in-one standard proteins to set
up the parameters. The optimal detection parameter of
mass/charge size range was set between 2000 and 10000
M/Z with a maximum of 50000 M/Z. The laser intensity
was set at 175 and detector sensitivity was set at 5. An aver-
age value of 130 spots was presented for each sample. All
samples were detected with the same parameters. All the
raw data was normalized with the ProteinChip Software
version 3.1 (homogenization of the total ion strength and
M/Z). The M/Z sample peaks with more than 2000 M/Z
were normalized with biomarker wizard of ProteinChip
Software version 3.1 for noise filtering. The first threshold
for noise filtering was set at 5, and the second was set at 2.
The minimum threshold for clustering was set at10%.
Spectrum analysis was performed using the Biomarker
Patterns Software.
5.3 Bioinformatics and biostatistics
Patients with HCC were split into a training set and a test-
ing set. The training sample set consisted of 33 HCC
patients and 33 healthy controls. The protein profiling
spectra obtained from the serum samples were normal-
ized using total ion current normalization from Cipher-
gen's ProteinChip Software version 3.1. Peak labeling was
performed by the Biomarker Wizard feature of this soft-
ware. The intensities of selected peaks were then trans-
ferred to Biomarker Pattern Software (BPS) as a 'root
node'. On the basis of peak intensity, a threshold was
determined by BPS to classify the root node into two child
nodes. If the peak intensity of a blind sample was lower
than or equal to the threshold, this peak would be labeled
as left-side child node. Peak intensities higher than the
threshold would be marked as right-side child node. After
multiple rounds of decision-making, BPS pooled all
labeled samples into a terminal node, where samples were
divided as cancer group or control group using the classi-
fication tree. Classification of the training set was made to
yield the least classification error.
The testing set consisted of serum samples from 48
patients with HCC and 33 control individuals. Using the
classification model generated from training dataset, BPS
evaluated all of the protein peak intensities for each sam-
ple in the testing dataset. It then discriminated HCC and
control samples according to their proteomic profile char-
acteristics. Model sensitivity was defined as the probabil-
ity of predicting HCC cases, while specificity was defined
as the probability of predicting healthy controls. A posi-
tive predictivity value was defined as the probability of
HCC if a test result was positive.
5.4 Biomarker purification and identification
Pooled serum samples (n = 6) from HCC patients with
high SELDI intensities at 7789 and 7984 m/z were
selected. These samples were diluted with 9 M urea, 10
mM Tris/HCI (Ph 7.4) and applied to AKTA Purifier T-900
column system [14]. After sample purification, albumin
and immunoglobulin were removed from the serum by 3
Isolation of the 7984 m/z peak Figure 3
Isolation of the 7984 m/z peak. Lane B, C and D: sam-
ples; Lane A, and E: molecular marker proteins. Arrow indi-
cates the band of 7984 m/z protein.
Table 5: Characteristics of the subjects
HCC patients (N = 48) Controls (N = 33)
Age (years) 46.0 ± 11.8 41.8 ± 10.8
Male/Female 39/9 24/9
Hepatitis B infection (%) 100% (0/48) 0% (0/33)
Hepatitis C infection (%) 0% (0/48) 0% (0/33)Proteome Science 2008, 6:10 http://www.proteomesci.com/content/6/1/10
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Peptide mass fingerprinting spectra of the 7984 m/z after trypsin digestion Figure 4
Peptide mass fingerprinting spectra of the 7984 m/z after trypsin digestion. The arrow indicates the peptide (1 
101.29 m/z) used for subsequent MS/MS analysis.
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Immunohistochemical staining of NAP-2 antibody in HCC tissues (A) and adjacent liver tissues (B) Figure 6
Immunohistochemical staining of NAP-2 antibody in HCC tissues (A) and adjacent liver tissues (B). The positive 
signals for NAP-2 were observed in brown (6A, red arrow). No positive signal of NAP-2 was detected in adjacent normal liver 
tissues (6B).Proteome Science 2008, 6:10 http://www.proteomesci.com/content/6/1/10
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GA and then by Protein A. The rest of the fractions were
loaded onto a Tricine-SDS-PAGE gel according to the
methods of Fountoulakis and Schagger [34,35], using
ETTAN II (Amersham Pharmacia) gel electrophoresis sys-
tem.
Electrophoresis was run at 20 mA for 3 hr. Gels were then
stained with Coomassie Brillian Blue. The bands corre-
sponding to the 8000 m/z markers were excised and then
destained with two washes of 50 µl deionised water, fol-
lowed with 50 µl ACN/50 mM/L NH4HCO3 (1:1, v/v),
and dried in a SpeedVac concentrator. The dried gel slices
were rehydrated with 10 mM DTT followed by 50 mM
IAM (45 min at room temperature in the dark). After sev-
eral washes with 25 mM NH4HCO3 and 100% CAN, 20
mg/L-solution of trypsin was added to the gel slices and
digestion was allowed to proceed at 37°C for 12 hr.
The trypsin digested sample was loaded onto a C18
reversed-phase column (5 mm × 250 µm, PepMapC18,
LC Packings, Amsterdam, The Netherlands), and the pep-
tides were separated by electros pray ionization (ESI,
Bruker Esquire 3000, Bruker Daltonik, Bremen, Ger-
many). Proteins were identified by an automated search-
ing algorithm against the SWISS-Protand NCBI protein
database.
5.5 Immunohistochemistry (IHC)
HCC tissues and adjacent liver tissues (control) were proc-
essed according to standard approaches [36]. The anti-
NAP-2 serum (1:1600, Immunechem Pharmaceuticals
INC, Canada) was applied to both HCC and control slides
and incubated in a moist chamber at 4°C overnight. 0.01
ml PBS was used as the negative control in all experi-
ments. Slides cut in parallel to the IHC-treated sections
were stained by HE for better identification of the differ-
ent tissue areas. To avoid interindividual bias of IHC
staining differentiations, all slides were determined by an
experienced pathologist.
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